Effect of riboflavin supplementation on plasma homocysteine in elderly people with low riboflavin status
- 1 September 2002
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in European Journal of Clinical Nutrition
- Vol. 56 (9), 850-856
- https://doi.org/10.1038/sj.ejcn.1601402
Abstract
To investigate the effect of riboflavin supplementation on plasma homocysteine (tHcy) concentrations in healthy elderly people with sub-optimal riboflavin status. A double-blind, randomized, placebo-controlled riboflavin supplementation trial. Community based study in Northern Ireland. From a screening sample of 101 healthy elderly people, 52 had sub-optimal riboflavin status (erythrocyte glutathione reductase activation coefficient, EGRAC>or=1.20) and were invited to participate in the study. The intervention had two parts. Part 1 was a 12 week randomized double blind, placebo-controlled intervention with riboflavin (1.6 mg/day). Following completion of part 1, the placebo group went on to part 2 of the study which involved supplementation with folic acid (400 micro g/day) for 6 weeks followed by folic acid and riboflavin (1.6 mg/day) for a further 12 weeks, with a 16 week washout period post-supplementation. The purpose of part 2 was: (a) to address the possibility that homocysteine-lowering in response to riboflavin may be obscured by a much greater effect of folate, and that, once folate status was optimized, a dependence of homocysteine on riboflavin might emerge; and (b) to demonstrate that these subjects had homocysteine concentrations which could be lowered by nutritional intervention. Although riboflavin supplementation significantly improved riboflavin status in both parts 1 and 2 of the study (P<0.001 for each), tHcy concentrations were unaffected (P=0.719). In contrast, folic acid supplementation (study part 2) resulted in a homocysteine lowering of 19.6% (P=0.001). Despite the metabolic dependency of tHcy on riboflavin, it did not prove to be an effective homocysteine-lowering agent, even in the face of sub-optimal riboflavin status.Keywords
This publication has 26 references indexed in Scilit:
- Association between B vitamin intake and plasma homocysteine concentration in the general Dutch population aged 20–65 yThe American Journal of Clinical Nutrition, 2001
- Homocyst(e)ine and Cardiovascular Disease: A Critical Review of the Epidemiologic EvidenceAnnals of Internal Medicine, 1999
- The structure and properties of methylenetetrahydrofolate reductase from Escherichia coli suggest how folate ameliorates human hyperhomocysteinemia.Nature Structural & Molecular Biology, 1999
- Relationships between micronutrient intake and biochemical indicators of nutrient adequacy in a ‘free-living’ elderly UK populationBritish Journal of Nutrition, 1997
- Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (> or = 40 micromol/liter). The Hordaland Homocysteine Study.JCI Insight, 1996
- A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductaseNature Genetics, 1995
- Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identificationNature Genetics, 1994
- Plasma homocysteine before and after methionine loading with regard to age, gender, and menopausal statusEuropean Journal of Clinical Investigation, 1992
- Methionine metabolism in mammalsThe Journal of Nutritional Biochemistry, 1990
- The effect of riboflavin deficiency on methylenetetrahydrofolate reductase (NADPH)(EC1.5.1.20) and folate metabolism in the ratBritish Journal of Nutrition, 1986